{"id":"NCT02438826","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Galcanezumab in Participants With Chronic Cluster Headache","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-18","primaryCompletion":"2018-03-27","completion":"2019-08-14","firstPosted":"2015-05-08","resultsPosted":"2019-06-11","lastUpdate":"2020-08-25"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cluster Headache"],"interventions":[{"type":"DRUG","name":"Galcanezumab 300 mg","otherNames":["LY2951742"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Galcanezumab 300 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.","primaryOutcome":{"measure":"Overall Mean Change From Baseline in Weekly Cluster Headache Attack Frequency","timeFrame":"Baseline, Week 1 through Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-4.59,"sd":0.79},{"arm":"Galcanezumab 300 mg","deltaMin":-5.38,"sd":0.81}],"pValues":[{"comp":"OG000 vs OG001","p":"0.334"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":48,"countries":["United States","Belgium","Canada","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["38162453","32050782"],"seeAlso":["http://www.lillytrialguide.com/EN-us/studies/headache/cgam"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":120},"commonTop":["Nasopharyngitis","Injection site pain","Influenza","Back pain","Fatigue"]}}